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ORIGINAL ARTICLE
Narrow band imaging optical diagnosis of small
colorectal polyps in routine clinical practice: the
Detect Inspect Characterise Resect and Discard 2
(DISCARD 2) study
Colin J Rees,1,2,3 Praveen T Rajasekhar,1,3 Ana Wilson,4 Helen Close,5
Matthew D Rutter,2,3,6 Brian P Saunders,4 James E East,7 Rebecca Maier,5
Morgan Moorghen,4 Usman Muhammad,5 Helen Hancock,5 Anthoor Jayaprakash,8
Chris MacDonald,9 Arvind Ramadas,10 Anjan Dhar,11 James M Mason12
ABSTRACT
Background Accurate optical characterisation and
removal of small adenomas (<10 mm) at colonoscopy
would allow hyperplastic polyps to be left in situ and
surveillance intervals to be determined without the need
for histopathology. Although accurate in specialist
practice the performance of narrow band imaging (NBI),
colonoscopy in routine clinical practice is poorly
understood.
Methods NBI-assisted optical diagnosis was compared
with reference standard histopathological findings in a
prospective, blinded study, which recruited adults
undergoing routine colonoscopy in six general hospitals
in the UK. Participating colonoscopists (N=28) were
trained using the NBI International Colorectal Endoscopic
(NICE) classification (relating to colour, vessel structure
and surface pattern). By comparing the optical and
histological findings in patients with only small polyps,
test sensitivity was determined at the patient level using
two thresholds: presence of adenoma and need for
surveillance. Accuracy of identifying adenomatous polyps
<10 mm was compared at the polyp level using
hierarchical models, allowing determinants of accuracy to
be explored.
Findings Of 1688 patients recruited, 722 (42.8%) had
polyps <10 mm with 567 (78.5%) having only polyps
<10 mm. Test sensitivity (presence of adenoma, N=499
patients) by NBI optical diagnosis was 83.4% (95% CI
79.6% to 86.9%), significantly less than the 95%
sensitivity (p<0.001) this study was powered to detect.
Test sensitivity (need for surveillance) was 73.0% (95%
CI 66.5% to 79.9%). Analysed at the polyp level,
test sensitivity (presence of adenoma, N=1620 polyps)
was 76.1% (95% CI 72.8% to 79.1%). In fully
adjusted analyses, test sensitivity was 99.4% (95% CI
98.2% to 99.8%) if two or more NICE adenoma
characteristics were identified. Neither colonoscopist
expertise, confidence in diagnosis nor use of high
definition colonoscopy independently improved test
accuracy.
Interpretation This large multicentre study
demonstrates that NBI optical diagnosis cannot currently
be recommended for application in routine clinical
practice. Further work is required to evaluate whether
variation in test accuracy is related to polyp
characteristics or colonoscopist training.
Trial registration number The study was registered
with clinicaltrials.gov (NCT01603927).
Significance of this study
What is already known on this subject?
A review of the available literature evaluating the
accuracy of narrow band imaging (NBI)–assisted
optical diagnosis compared with histological
assessment and recommendations from national
bodies suggested that optical diagnosis could
replace histology for diminutive polyps.
Additionally, exploratory work has suggested a
short learning curve for NBI-assisted optical
diagnosis, making it an attractive option that could
be applied widely into clinical practice, if minimal
training was required. Notably, the majority of
studies were performed by experts in the field of
optical diagnosis or in academic centres with
limited data from non-expert centres suggesting
that the accuracy may not be consistently
reproducible in non-expert hands. Confirming
whether NBI-assisted optical diagnosis can
reproducibly achieve the required level of accuracy
is one of the most pressing questions within the
field of GI endoscopy. It is essential to establish its
accuracy before recommending its use in routine
clinical practice.
What are the new findings?
This is the largest multicentre diagnostic study in
this field. The study demonstrates that NBI-assisted
optical diagnosis cannot currently be
recommended for routine use outside of expert
centres. The accuracy, both at polyp and patient
level, was substantially below recommended levels.
Importantly, polyp level analyses identified that
accuracy was acceptable when two or more of the
features of the NBI International Colorectal
Endoscopic (NICE) classification system were
positively identified. Possible explanations are that
not all polyps exhibit NICE characteristics or that
colonoscopists vary in their ability to identify these
characteristics.
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INTRODUCTION
Colorectal cancer (CRC) is a leading cause of morbidity and
mortality in the Western world.1
Most CRCs develop from adenomas in a well-described
adenoma–carcinoma genetic sequence.2 Colonoscopy with poly-
pectomy interrupts this sequence, reducing the rate of subse-
quent CRC and associated mortality by 40–60%.3 4
Consequently, national bowel cancer screening programmes
(BCSPs) have been developed, with over 14 million screening
colonoscopies performed annually in the USA alone.5 Improved
training, technology and awareness of colonoscopic quality have
led to increased polyp detection rates. Over 90% of polyps
detected at colonoscopy are small (6–9 mm) or diminutive
(≤5 mm), with the latter forming the majority.6 7 Cancer risk or
advanced features (villous elements or high-grade dysplasia) par-
ticularly in diminutive polyps is low.8 The incidence of dysplas-
tic serrated polyps, thought to be precursors of cancer via an
alternative pathway, is lower still, 0.3–0.5%.6 7 9
Approximately half of small polyps are non-neoplastic with
the majority of these being hyperplastic6 7; therefore, many
polypectomies are performed unnecessarily, increasing
procedure-related risks such as bleeding and perforation.
Currently, even diminutive polyps are resected and examined
histologically. The number of adenomas detected is one of the
best determinants of long-term risk of advanced neoplasia and
informs surveillance decision-making. Diagnosing small polyps
by optical diagnosis would allow recto-sigmoid hyperplastic
polyps, with no malignant potential, to be diagnosed and left in
situ and small adenomas to be resected and discarded without
histopathology. Additionally, a positive diagnosis could be made
for small polyps not retrieved or unsuitable for histological ana-
lysis.10 Optical diagnosis would enable immediate determination
of surveillance intervals, with associated time and cost savings.
Traditional white light technology, used at routine colonos-
copy, is not accurate enough for optical diagnosis to replace
routine histopathological assessment. However, a number of
image-enhancing, user-friendly technologies have been devel-
oped. NBI (Olympus, Japan) has been the most widely studied.
It is a ‘blue light’ optical imaging modality operated by a button
on the colonoscope that, by enhancing mucosal detail and vas-
cular structures, allows assessment of microvascular density.11
Neoplastic tissue is characterised by increased angiogenesis
making adenomas appear darker using NBI.12 The learning
curve to accurately assess microvascularity appears to be short,13
making it an attractive and practical option for optical
diagnosis.
A large meta-analysis of 56 studies using NBI for optical diag-
nosis found overall sensitivity to be 91.0% (95% CI 88.6–
93.0%), specificity 85.6% (95% CI 81.3–89.0%) and negative
predictive value of 82.5% (95% CI 75.4–87.9%).14 Another
systematic review and meta-analysis of optical diagnosis for
diminutive polyps suggested that accuracy was higher in aca-
demic centres and when performed by experienced endosco-
pists; however, only 3 of 20 NBI studies were undertaken in
non-academic settings.15
Detect Inspect Characterise Resect and Discard (DISCARD) 2
was designed to determine whether clinical management based
on NBI-assisted optical diagnosis is accurate in routine clinical
practice outside academic centres.
METHODS
Study design
A UK multicentre, prospective, blinded study comparing surveil-
lance intervals determined by NBI-assisted optical diagnosis and
histological assessment in patients referred for colonoscopy.
Hypotheses
NBI-assisted optical diagnosis correctly characterises small
colonic polyps as adenomas or hyperplastic, allowing assign-
ment of surveillance intervals with 95% sensitivity compared
with histological assessment.
Patients
Adult patients referred for non-emergency colonoscopy (symp-
tomatic referrals and Faecal Occult Blood positive (FOBT)
BCSP referrals) between July 2012 and February 2014 were
invited to participate and written informed consent obtained.
All patients entered Phase 1 of the study, undergoing colonos-
copy following standard clinical practice. Patients found to have
one or more polyps <10 mm in size entered Phase 2 of the
study. Patients with known IBD (UC or Crohn’s disease), polyp-
osis syndromes, pregnancy or lack of capacity to give informed
consent were excluded.
Setting
Six NHS hospitals in the North of England participated, with a
maximum of five recruiting colonoscopists per site. The UK
NHS BCSP offers colonoscopy to patients between 60 and
74 years of age with evidence of faecal occult blood, with colon-
oscopy performed by accredited screening colonoscopists. BCSP
colonoscopists may represent a particularly specialised popula-
tion of endoscopists: to provide generalisable results a
maximum of two BCSP colonoscopists were allowed per site.
Training
Colonoscopists underwent training and assessment on the use of
NBI in polyp characterisation using a previously validated NBI
training module, including the use of the NICE classification16
(table 1). Colonoscopists had to achieve 90% accuracy for
optical diagnosis in the post-training test, with two attempts
allowed.12 All procedures were performed using Olympus
equipment (Olympus Lucera or Elite processors and 240 or 260
series endoscopes).
NBI-assisted optical assessment
During colonoscopy, polyps <10 mm were evaluated with both
white light and NBI. Polyp site, size (measured using an instru-
ment of known size), morphology (Paris Classification)17 and
resection method were recorded. Using NBI and NICE classifi-
cation (table 1), colonoscopists documented polyp colour,
microvessel type and surface pattern, and classified each as
adenoma, hyperplastic, cancer or other. Colonoscopists also
recorded their diagnostic confidence as high or low. High
Significance of this study
How might it impact on clinical practice in the
foreseeable future?
The results of this study confirm that optical diagnosis cannot
be recommended for use in routine clinical practice. Further
research is required to understand what factors influence the
reported variation in the accuracy of NBI-assisted optical
diagnosis in this study. This research should focus on polyp and
colonoscopist characteristics and training methods.
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confidence indicated hypothetically that the colonoscopist
would have discarded the polyp without histological assessment,
while low confidence indicated sending the polyp for histology.
Confidence was considered during polyp level analysis only.
Where all polyps identified in a patient were <10 mm, a surveil-
lance interval (using the British Society for Gastroenterology
(BSG) guidelines) based on optical diagnosis was assigned and
recorded.18 All polyps were resected by snare polypectomy or
by excision biopsy removal and sent for histological assessment.
However, if multiple rectal hyperplastic polyps were found,
endoscopists were not required to remove all and removal or
sampling was done for the first five only. Colonoscopists were
given feedback on their optical diagnosis accuracy after every 30
polyps assessed and were informed how well their optical diag-
nosis correlated with histopathology at per polyp level. No add-
itional training was given during the study period. Endoscopists
were not required to differentiate sessile serrated polyps (SSPs).
Histology
Histological assessment using standard H&E staining was per-
formed. Histopathologists classified specimens according to
WHO guidelines, blinded to endoscopic images and assess-
ments. A subset from each centre was reviewed by an external
specialist GI pathologist. Histological results were returned to
lead investigators who, blinded to colonoscopic findings,
assigned surveillance intervals per patient providing the refer-
ence standard for surveillance. All retrieved polyps <10 mm
were characterised by NBI-assisted optical diagnosis and hist-
ology, with histological findings providing the reference stand-
ard for assessing optical diagnosis accuracy. All polyps <10 mm
were included in polyp-level assessment whether patients had
larger polyps or not.
Outcome measures
Patient-level test sensitivity was assessed at two thresholds com-
paring optical diagnosis with the histology reference standard:
1. Presence of an adenoma (including high-risk,
intermediate-risk and low-risk findings).
2. Need for surveillance (where some low-risk patients are
judged not to require surveillance).
Additionally, three further definitions of test accuracy were
assessed:
1. Exact surveillance interval (precise agreement of surveillance
interval by optical diagnosis and histology).
2. Conservative matching (correctly identifying or overspecify-
ing need for surveillance)
3. Error rate (false-positive or false-negative diagnosis of
adenoma)
In addition to patient-level analyses, factors influencing the
accuracy of diagnosis were explored at the polyp level, including
patient, organisational, colonoscopist and polyp variables.
Adverse events
Although there are no known complications of NBI-optical
diagnosis, patients were monitored for procedure-related side
effects and complications. Adverse events were recorded for
30 days post-procedure in phase II patients.
Sample size
The study was designed to estimate the test sensitivity of 95%
(with 95% CI ±2.5%), based on 290 patients with at least one
adenoma (<10 mm) but only small or diminutive polyps requir-
ing determination of a surveillance interval. Using data from
DISCARD and audit,19 an initial phase I sample size of 2500
was estimated based on 20% of patients having only small or
diminutive polyps (500); 70% of small polyps anticipated to be
adenomas (350) and up to 15% of patients having incomplete
histology.20 An interim review indicated that significantly more
than 20% of patients had polyps; therefore, the sample size was
revised to 1400 phase I patients. Exceeding target recruitment
with 1700 patients ensured eligibility criteria for the primary
outcome were achieved.
Statistical analyses
Test performance was estimated using proportions with CIs
(Clopper–Pearson) using STATA IC V.13.1 StataCorp.
Exploration of variables at polyp level was performed using
xtlogit, where proportions were estimated from models using
reported ORs. Modelling provided a hierarchical structure of
polyp within patient; population average estimates were used
(to prevent overweighting by patients with more numerous
polyps) and reported using robust SEs.
Ethical approval
The study was given a favourable ethical opinion by UK
National Research Ethics Committee North East-Newcastle and
North Tyneside. Approval was gained from the NHS BCSP
Research Committee. A study steering committee provided
study oversight. The study was registered with clinicaltrials.gov
(NCT01603927). Study reporting followed the STARD state-
ment (http://www.stard-statement.org).
RESULTS
Patients
Between July 2012 and February 2014, 1688 patients referred
for colonoscopy were recruited into phase I across the six par-
ticipating hospitals: 722 patients (42.8%) had small or diminu-
tive polyps with 567 (78.5%) having only polyps <10 mm
(figure 1). Mean patient age was 64.3 years (IQR 55.0 to 70.2)
and 53.1% were male. Patients were colonoscoped using high
definition (HD, 22%) or standard definition (SD, 78%)
imaging. Table 2 reports factors associated with higher polyp
detection levels at the patient level. The only comorbidity sig-
nificantly more common in patients with polyps was diabetes
mellitus (20.3% vs 10.4%, p<0.001).
Patient-level analysis
From the phase I cohort, 722 patients (assessed by 28 colonos-
copists) had at least one polyp <10 mm and entered phase II.
Of these, 567 had only small or diminutive polyps permitting
patient-level analysis for surveillance interval. A surveillance
interval determined by optical diagnosis was unavailable for
Table 1 NICE classification
Polyp classification using NBI
Colour (S) Same or lighter than the
background mucosa
(B) Browner relative to
background mucosa
Vessels (N) None or isolated lacy
vessels
(T) Thick brown vessels
surrounding white structures*
Surface
pattern
(D) Dark or white spots of
uniform size or homogeneous
absence of pattern
(O) Oval, tubular or branched
white structures* surrounded
by brown vessels
Most likely
pathology
Hyperplastic Adenoma
*These structures may represent the pits and the epithelium of the crypt opening.
NBI, narrow band imaging; NICE, NBI International Colorectal Endoscopic.
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3.7% (incomplete data), and surveillance interval determined by
histology was unavailable for 11.1% (non-retrieval of polyps or
incomplete histology assessment). Comparison of surveillance
interval was possible in 499 patients. Of these 499 patients, 452
patients (90.6%) had only diminutive polyps.
Using the threshold of the presence of one or more adenomas
(including all high-risk, intermediate-risk and low-risk patients),
test sensitivity of optical diagnosis was 83.4% (95% CI 79.6%
to 86.9%) (tables 3 and 4). Test sensitivity (correctly identifying
need for surveillance vs no surveillance) was 73.0% (95% CI
66.5% to 79.9%). Both measures were considerably lower than
the 95% requirement (p<0.001) set by the study team. When
considering exact or conservative matching, test accuracy was
67.9% (64.1% to 71.9%) and 87.6% (84.6% to 90.4%). In
post hoc analyses, when considering only diminutive polyps
(<6 mm) test sensitivity of optical diagnosis for detecting
adenoma was 83.7% (95% CI 79.5% to 87.4%) and for surveil-
lance was 74.2% (95% CI 66.8% to 80.8%).
Polyp-level analysis
The accuracy of NBI-assisted optical diagnosis was explored
using polyp-level data comparing optical and histological diag-
noses (adenoma vs non-adenoma). In total, 722 patients pro-
vided data on 1620 retrieved polyps, with individual patients
providing between 1 and 27 polyps (mean 2.2). Of 1620 polyps
retrieved, 1580 were characterised by optical diagnosis and
1540 by histology (table 5). A description of polyp character-
istics at the polyp level determined by optical diagnosis is shown
in table 6. Of these polyps, 73.7% were diminutive and 26.3%
were small. Of 1014 adenomas identified by histology, the grade
of dysplasia was 1 (0.1%) cancer, 3 (0.3%) high-grade dysplasia,
1005 (99.1%) low-grade dysplasia and 5 (0.5%) unreported
dysplasia grade. The cancerous polyp was a 5 mm Is lesion
found in the sigmoid colon and removed by cold snare poly-
pectomy; the optical diagnosis was given with high confidence
as adenoma. A villous component was found in 49 (4.8%) aden-
omas and 964 (95%) were non-villous (status not recorded in
1). Three polyps were histologically reported as SSPs.
Determinants of test accuracy were explored on the subset of
polyps graded as adenoma or hyperplastic by NBI and histology
(1369/1620, 85% of cases, table 5). In an unadjusted hierarch-
ical model, NBI provided test sensitivity of 76.1% (table 7,
model (1)) similar to the patient-level analysis. A number of
variables fitted this base model in simple adjusted regression
analyses; however, only the presence of NICE polyp character-
istics (p<0.001) and polyp size (p<0.05) fitted a fully adjusted
multivariable model (table 7).
NICE characteristics
When considering NICE polyp characteristics test sensitivity at
polyp level was 99.9% (95% CI 97.8% to 100.0%), where all
three characteristics suggestive of an adenoma were positively
identified (T=Thick brown vessels surrounding white structures,
B=Browner relative to background, O=Oval, tubular or
branched white structures surrounded by brown vessels). If ≥2
characteristics were identified, then the sensitivity was 99.4%
(95% CI 98.2% to 99.8%). Of 1369 polyps included, 727
(53.1%) were graded T; 779 (56.9%) graded O and 799
(58.4%) graded B. In combination, 651 (47.6%), 113 (8.3%),
126 (9.2%) and 479 (35.0%) had three, two, one and no
characteristics, respectively.
Confidence, expertise, image resolution and colonic site
In univariable analyses, test sensitivity was significantly greater
with BCSP expertise (yes: 83.0% vs no: 64.1%, p<0.001).
Confidence in polyp diagnosis (yes: 77.1% vs no: 72.0%,
p=0.19) was not significant. However, neither expertise nor
confidence were independently important influence in the final
adjusted model. Colonoscopists reported high confidence asses-
sing 78.1% of polyps (table 6). Further exploration of confi-
dence in patients with two or more NICE signs showed no
difference in polyp diagnoses with high and low confidence.
Image resolution did not affect test sensitivity: univariable ana-
lyses test sensitivity for HD: 77.3% vs SD: 75.8% (p=0.65).
Test sensitivity was not affected by the site of polyp in the
colon.
External review of histopathology
Repeat histology was conducted on 193 polyps of which 189
were assessable (12% total polyps). The disagreement rate was
3.4% or 11.1% depending on narrow or inclusive definition of
matching. The narrow definition compared only adenoma and
hyperplasia matching; the inclusive definition included other
categories used either by original or review histology. External
review showed that histopathology did not provide a perfect ref-
erence standard.
Adverse events
During phase II, 55 adverse events were reported. Four were
serious but only one (mild bleeding post polypectomy) was col-
onoscopy related. No perforations occurred among patients
recruited to this trial.
DISCUSSION
This largest multicentre prospective community study to date,
evaluating the use of NBI-assisted optical diagnosis in routine
clinical practice demonstrates that optical diagnosis in the hands
of non-experts is not currently accurate enough to replace hist-
ology in determining surveillance for patients with colonic
Figure 1 Patient flowchart.
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Table 2 Screened cohort characteristics
Patients with no
polyps
Patients with small
polyps
Patients with other
findings Total patients
N=883 Per cent N=567 Per cent N=238 Per cent N=1688 Per cent p Value*
Polyps
No polyps 883 100.0 0 0.0 0 0.0 883 52.3 <0.001
Only small polyps (<10 mm) 0 0.0 567 100.0 0 0.0 567 33.6
Small and large polyps 0 0.0 0 0.0 150 63.0 150 8.9
Only large polyps 0 0.0 0 0.0 58 24.4 58 3.4
Polyps and other findings 0 0.0 0 0.0 16 6.7 16 0.9
No polyps, cancer suspected 0 0.0 0 0.0 14 5.9 14 0.8
Incomplete colonoscopy 54 6.1 1 0.2 9 3.8 64 3.8 <0.001
Discomfort-tortuosity related 32 59.3 0 0.0 7 77.8 39 60.9 0.011
Preparation-related 21 38.9 0 0.0 1 11.1 22 34.4
Other 1 1.9 1 100.0 1 11.1 3 4.7
Site
County Durham and Darlington 260 29.4 164 28.9 61 25.6 485 28.7 <0.001
North Cumbria 38 4.3 28 4.9 9 3.8 75 4.4
North Tees and Hartlepool 166 18.8 156 27.5 88 37.0 410 24.3
Northumbria 70 7.9 37 6.5 24 10.1 131 7.8
South Tees 193 21.9 65 11.5 20 8.4 278 16.5
South Tyneside 156 17.7 117 20.6 36 15.1 309 18.3
Age (years); median, IQR 62.2 49.8–68.3 65.9 60.0–70.4 66.7 62.3–72.4 64.3 55.0–70.2 <0.001
Gender
Female 488 55.3 218 38.4 86 36.1 792 46.9 <0.001
Male 394 44.7 349 61.6 152 63.9 895 53.1
Ethnicity
White—British 866 99.3 560 98.8 235 99.6 1661 99.2 0.218
Asian or Asian British 5 0.6 2 0.4 0 0.0 7 0.4
Black or Black British 0 0.0 1 0.2 0 0.0 1 0.1
Chinese or other ethnic groups 1 0.1 1 0.2 1 0.4 3 0.2
White—other 0 0.0 3 0.5 0 0.0 3 0.2
Smoking
Current smoker 142 16.3 122 21.5 40 16.9 304 18.2 <0.001
Previous smoker 321 36.9 250 44.1 113 47.7 684 40.9
Never smoked 407 46.8 195 34.4 84 35.4 686 41.0
Alcohol use 522 60.1 365 64.5 166 69.7 1053 63.0 0.016
Units/week (users); median, IQR 9.0 4.0–16.0 14.0 6.0–23.5 14.0 6.0–27.0 11.0 5.0–20.0 <0.001
Taking any regular medication 720 81.5 499 88.0 198 83.5 1417 84.0 0.004
Taking an NSAID 81 11.2 38 7.6 11 5.5 130 9.1 0.018
Taking a statin 245 33.8 260 52.1 114 56.7 619 43.4 <0.001
Taking aspirin 138 19.1 122 24.4 50 25.0 310 21.8 0.040
Primary reason for colonoscopy
BCSP 162 18.3 190 33.5 124 52.1 476 28.2 <0.001
Change in bowel habit 276 31.3 132 23.3 37 15.5 445 26.4 <0.001
Surveillance procedure 122 13.8 137 24.2 34 14.3 293 17.4 <0.001
Per-rectal bleeding 130 14.7 59 10.4 28 11.8 217 12.9 0.050
Iron-deficiency anaemia 122 13.8 60 10.6 13 5.5 195 11.6 0.001
Other 122 13.8 19 3.4 22 9.2 163 9.7 <0.001
Abdominal pain 93 10.5 32 5.6 8 3.4 133 7.9 <0.001
Weight loss 34 3.9 23 4.1 5 2.1 62 3.7 0.389
Family history 30 3.4 25 4.4 5 2.1 60 3.6 0.274
Abnormal imaging 9 1.0 2 0.4 2 0.8 13 0.8 0.396
Previous colonoscopy, within 10y 336 38.1 272 48.0 79 33.3 687 40.7 <0.001
Previous colorectal cancer (CRC) 32 3.6 16 2.8 3 1.3 51 3.0 0.161
Previous CRC (years); median, IQR 5.5 3.9–6.8 4.8 1.6–10.2 10.7 4.8–63.8 5.5 3.3–9.6 0.441
Family history of CRC† 181 20.5 120 21.2 40 16.8 341 20.2 0.352
*Three-way Fisher’s exact test for counts, three-way Kruskal–Wallis test for continuous measures.
†A: Two or more first-degree relatives or one first-degree relative <45 years old; B: one first-degree relative >45 years old; C: one or more second-degree or third-degree relative(s);
D: none.
BCSP, Bowel Cancer Screening Programme; NSAID, non-steroidal anti-inflammatory drug.
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polyps. Regardless of the threshold employed, test sensitivity
was significantly below required levels and below those reported
in academic centres, which report concordance between optical
and histology-based surveillance intervals of >90%.19 21
The Preservation and Incorporation of Valuable Endoscopic
Innovations (PIVI) statement issued by the American Society of
GI Endoscopy has issued advice on acceptable performance
thresholds for real-time endoscopic assessment of diminutive
polyps required before optical diagnosis should be recom-
mended for routine clinical practice.22 The PIVI statement
advises that optical diagnosis can be used for diminutive (1–
5 mm) and histological diagnosis for small (6–9 mm) polyps and
those summated results used to determine surveillance. In
expert hands, optical diagnosis of small polyps using white light
and NBI has been shown to be comparable to histology.19 21 A
large meta-analysis showed per polyp sensitivity of 91% and
specificity of 83%,23 but results from general settings have not
replicated those values, with sensitivities ranging from 75% to
94% and specificity 65% to 76%.24–26 The present study used
optical diagnosis for both small and diminutive polyps to
determine surveillance interval but as 91% of patients had only
diminutive polyps, the inclusion of small polyps did not signifi-
cantly affect determination of surveillance interval. Accuracy of
adenoma characterisation at the polyp level in the present study
was 83%. The NHS BCSP provides a high standard of practice
with colonoscopists accredited and regularly quality assured. In
this study, performance was better for screening colonoscopists
in univariable analysis but not in adjusted models. A
meta-analysis reported that pooled negative predictive value was
higher when optical diagnosis was made with high confidence as
opposed to when no information on confidence was given (93%
vs 88%) as well as higher agreement in surveillance intervals for
high confidence (91% vs 79%).15 Non-experts in community
practice made 49% of diagnoses with high confidence before
training and 72% after training in optical diagnosis.27 Some
studies assessing experienced endoscopists have reported high
confidence optical diagnosis in over 85% of cases.28 The
current study found that high confidence predictions were made
in 78.1% of polyps but confidence did not influence test
accuracy.
A Discard policy relies on accurate estimation of polyp size. It
is recommended that polyp size is estimated against an instru-
ment of known size such as an open biopsy forceps. Even using
such an approach, estimation of size maybe inaccurate.29 Tools
such as the endoscopic lesion measurement system have been
developed. This consists of a graduated measurement device that
Table 3 Test performance: need for patient surveillance
Histology interval (reference standard)
High risk:
1 year
Intermediate
risk: 3 years
Low risk:
5 years
Low risk:
no surveillance
No adenoma:
no surveillance Total
NBI colonoscopy interval
High risk: 1 year (a) 9 4 0 (b0) 3 (b) 2 18
Intermediate risk: 3 years 3 30 12 10 2 57
Low risk: 5 years 2 13 46 52 13 126
Low risk: no surveillance (c0) 0 4 9 (d0) 100 19 132
No adenoma: no surveillance (c) 0 4 27 28 (d) 107 166
Total 14 55 94 193 143 (N) 499
Adenoma present (solid line partitions)
Test sensitivity=sum of cells in box (a)/sum of cells in boxes (a)+(c)=297/356=83.4%.
Test specificity=sum of cells in box (d)/sum of cells in boxes (d)+(b)=107/143=74.8%.
Error rate=(b+c)/N=95/499=19.0%.
Surveillance required (dashed line partitions)
Test sensitivity=sum of cells in box (a)/sum of cells in boxes (a)+(c0)=119/163=73.0%.
Test specificity=sum of cells in box (d0)/sum of cells in boxes (d0)+(b0)=254/336=75.6%.
Exact matching=sum of cells with matching surveillance interval / N=339/499=67.9%.
Conservative matching=sum of cells with matching or over surveillance/N=437/499=87.6%.
Error rate=(b0+c0)/N=126/499=25.2%.
NBI, narrow band imaging.
Table 4 Test performance: summary findings
NBI colonoscopy vs histology (reference) Estimate (%) 95% CI
Adenoma (yes/no)*
Sensitivity 83.4 79.6% to 86.9%
Specificity 74.8 67.6% to 81.1%
PPV 89.2 85.9% to 92.4%
NPV 64.5 57.3% to 71.8%
Surveillance (yes/no)*
Sensitivity 73.0 66.5% to 79.9%
Specificity 75.6 70.9% to 80.1%
PPV 59.2 52.3% to 66.0%
NPV 85.2 81.0% to 89.1%
Exact match 67.9 64.1% to 71.9%
Conservative match 87.6 84.6% to 90.4%
*For explanation see table 3.
NBI, narrow band imaging; NPV, negative predictive value; PPV, positive predictive
value.
Table 5 Polyps: optical and histological determination
Histology diagnosis (reference standard)
Hyperplastic Adenoma Other Not possible Total
NBI colonoscopy
Hyperplastic 305 210 75 29 619
Adenoma 82 772 45 40 939
Other 7 8 6 1 22
Not possible 6 24 0 10 40
Total 400 1014 126 80 1620
NBI, narrow band imaging.
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can be passed down the biopsy channel and placed alongside the
lesion to aid measurement and has been shown to be superior to
clinician estimation.30 Such systems warrant further evaluation as
size is a fundamental part of a potential Discard policy.
The rate of SSPs reported in this study is low when compared
with the reported prevalence of 0.3–0.5%.31 One study has sug-
gested that the use of NBI might improve the detection of SSPs
although the increase detected did not reach statistical signifi-
cance.32 In the present study, colonoscopists were asked to clas-
sify polyps as adenomas, hyperplastic, cancer or other and were
not expected to specifically diagnose sessile serrated adenomas or
polyps. Recent work has highlighted typical endoscopic features
that may be used to distinguish SSPs from hyperplastic polyps.33
These features, together with the NICE classification, have been
combined to develop the Workgroup serrAted polypS and
Polyposis (WASP) classification. Using WASP, it has been shown
that, following training, an accuracy of optical diagnosis for SSA/
Ps 0.87 (95% CI 0.80 to 0.95) could be achieved when diagnoses
were made with high confidence. Six months after training,
accuracy was 0.84 (95% CI 0.81 to 0.88) when made with high
confidence. The use of the WASP classification could be incorpo-
rated into future training modules in optical diagnosis.
Accurate adenoma identification by NBI was heavily depend-
ent on identification of the three NICE polyp characteristics. If
two or more features were present (55.9% of polyps), the sensi-
tivity for correctly identifying adenomas exceeded 99%. The
discrepancy between this finding and overall test sensitivity,
combined with a high percentage of high confidence diagnoses,
raises the possibility that endoscopists were relying on factors
other than NICE criteria to make the optical diagnosis. Where
NICE features were identified, accuracy was high but the
present study cannot determine whether NICE features were
Table 6 Characterisation of polyps retrieved, by histological determination
Adenoma* Hyperplastic* Other/not determined* Total
N=1014 Per cent N=400 Per cent N=206 Per cent N=1620 Per cent
Polyp size
Diminutive (≤5 mm) 706 69.6 315 78.8 173 84.0 1194 73.7
Polyp site
Ascending colon 188 18.5 19 4.8 24 11.7 231 14.3
Caecum 119 11.7 18 4.5 34 16.5 171 10.6
Descending colon 99 9.8 22 5.5 21 10.2 142 8.8
Distal transverse colon 97 9.6 20 5.0 17 8.3 134 8.3
Hepatic flexure 73 7.2 19 4.8 12 5.8 104 6.4
Proximal transverse colon 71 7.0 15 3.8 6 2.9 92 5.7
Rectum 94 9.3 146 36.5 38 18.4 278 17.2
Sigmoid 204 20.1 130 32.5 41 19.9 375 23.1
Sigmoid descending 8 0.8 4 1.0 2 1.0 14 0.9
Splenic flexure 61 6.0 5 1.3 8 3.9 74 4.6
Not recorded 0 0.0 2 0.5 3 1.5 5 0.3
Polyp shape
Ip 40 3.9 9 2.3 4 1.9 53 3.3
Ips 117 11.5 27 6.8 12 5.8 156 9.6
Is 478 47.1 208 52.0 101 49.0 787 48.6
IIa 349 34.4 149 37.3 83 40.3 581 35.9
IIa/c 2 0.2 0 0.0 0 0.0 2 0.1
IIb 20 2.0 3 0.8 5 2.4 28 1.7
Not recorded 8 0.8 4 1.0 1 0.5 13 0.8
Polyp resection
Cold biopsy 171 16.9 168 42.0 69 33.5 408 25.2
Cold snare 540 53.3 146 36.5 89 43.2 775 47.8
Endoscopic mucosal resection 44 4.3 13 3.3 5 2.4 62 3.8
Hot biopsy 22 2.2 15 3.8 1 0.5 38 2.3
Hot snare 232 22.9 58 14.5 25 12.1 315 19.4
Not recorded 5 0.5 0 0.0 17 8.2 22 1.4
Confidence in optical diagnosis
High confidence 769 75.8 340 85.0 157 76.2 1266 78.1
NICE classification
Vessels: T 661 65.2 67 16.8 72 35.0 882 54.4
Surface pattern: O 696 68.6 85 21.3 76 36.9 800 49.4
Colour: B 726 71.6 82 20.5 74 35.9 857 52.9
None of the above 202 20.4 285 72.3 101 51.8 588 37.2
One of the above 92 9.3 40 10.2 23 11.8 155 9.8
Two of the above 101 10.2 13 3.3 14 7.2 128 8.1
Three of the above 595 60.1 56 14.2 57 29.2 708 44.8
*Data shown give proportions within groups and are unadjusted for hierarchy at the patient level.
NBI, narrow band imaging; NICE, NBI International Colorectal Endoscopic.
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not consistently present or features were incorrectly interpreted.
Previous studies suggest a short learning curve for optical diag-
nosis16 34; however, training using still images and videos may
not translate into accuracy in vivo. The current study is consist-
ent with a previous study where 12/13 community-based gastro-
enterologists identified adenomas with >90% accuracy
following training but only 3/12 managed this in vivo.25 This
was a pragmatic study designed to examine whether NBI
worked in clinical practice. While double reporting of histology
was undertaken to assess reliability and training and feedback
on NBI were given, it did not incorporate more formal testing
of reliability and did not aim to test explanatory factors related
to how NBI did or did not work.
As this was a pragmatic study generalisable to routine clinical
practice, the protocol did not mandate use of HD or SD colono-
scopes. Consequently, only 22% of patients (20% of polyps)
were assessed with HD, although this did not significantly alter
test sensitivity. Most studies that have achieved results compar-
able to reference standard have used HD systems15; however, a
meta-analysis of all NBI studies reported that HD significantly
decreased the performance of NBI, a possible explanation was
that some of these studies also used magnification, making data
more heterogeneous.14
Optical diagnosis remains an attractive idea because of the
potential for reducing costs and streamlining care. This study
demonstrates that correctly characterising diminutive polyps
using optical diagnosis represents a major challenge. One
method for improving accuracy could be the use of computer-
aided diagnosis, which has been shown to be feasible in a pilot
study.35 Should the accuracy of optical diagnosis be improved,
validated accreditation programmes and on-going quality assur-
ance would be required in order for it to be incorporated into
routine practice.
CONCLUSIONS
Previous research, predominantly from single sites and academic
groups, suggests that NBI-assisted optical diagnosis has accept-
able accuracy to determine surveillance without histology. These
findings were not replicated in this large, multicentre study of
NBI use in routine practice, either at the polyp or patient level.
The marked variation of accuracy according to the polyp
characteristics detected is notable: either a proportion of polyps
present without NBI detectable signs or colonoscopists vary in
their ability to evaluate them. The first explanation would
require imaging advances; the second further research into
training and accreditation. NBI-assisted optical diagnosis of
small polyps during colonoscopy cannot currently be recom-
mended for routine use outside of specialist centres.
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Table 7 Hierarchical regression modelling of adenoma detection
(1) Unadjusted model
Sensitivity 76.1% (72.8% to 79.1%)
Specificity 77.5% (71.0% to 82.8%)
Sensitivity (%) (95% CI)
(2) Model adjusted by polyp characteristics and combinations
None 6.5 (3.6% to 11.2%)
T 60.0 (31.5% to 83.0%
O 68.0 (44.5% to 85.0%)
B 56.8 (33.2% to 77.7%)
OB 94.9 (80.8% to 98.8%)
TO 96.7 (76.0% to 99.6%)
TB 97.3 (80.3% to 99.7%)
TOB 99.9 (97.8% to 100.0%)
(3) Model adjusted by number of polyp characteristics*
None 6.5 (3.6% to 11.4%)
1 of TOB 62.3 (42.7% to 78.6%)
2 of TOB 96.3 (88.5% to 98.9%)
3 of TOB 99.9 (97.9% to 100.0%)
Hierarchical regression models of polyps nested within patients (see Methods section).
Polyp categories:
None denotes a polyp without T, O or B observed.
T=Thick brown vessels surrounding white structures.
O=Oval, tubular or branched white structures surrounded by brown vessels.
B=Browner relative to background.
*Model 3 was rerun with two or three polyp characteristics combined giving a test
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